Company intelligence / Profile preview

Aptose Biosciences Inc.

Toronto, Ontario, Canadaaptose.com ↗

Ownership: Public · APTO
Development stage: Phase 2

Overview

Tuspetinib-based triple therapy (TUS+VEN+AZA) has shown promising early results in newly diagnosed AML patients, including complete remissions in difficult-to-treat TP53-mutated AML and FLT3-wildtype AML patients. The TUSCANY Phase 1/2 trial is ongoing with patients being treated at the 80 mg TUS dose level after successful completion of the 40 mg dose cohort.

Therapeutic areas: OncologyHematology
Modalities: Small molecule kinase inhibitors
Industry: Biotech

Drug pipeline

12 assets

GTI-2040

11 more assets in the full pipeline.

Request access →

Partnerships

Hanmi PharmaceuticalNational Cancer Institute (CRADA)

Financials

Market cap: $4.4M
Total revenue: $0
Enterprise value: $3.4M

Beyond the preview

Go deeper on Aptose Biosciences Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aptose Biosciences Inc..

Explore the full profile